Halotop Lotion contains halobetasol propionate 0.05% w/v, a potent topical corticosteroid indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Halobetasol exerts anti-inflammatory, antipruritic, and vasoconstrictive effects by inhibiting multiple inflammatory cytokines and mediators, thereby reducing erythema, edema, and itching associated with various skin conditions. Halotop Lotion is primarily prescribed for conditions such as psoriasis, eczema, atopic dermatitis, and lichen planus, where rapid symptomatic relief is desired. The formulation allows for effective penetration into the epidermis, ensuring targeted action with minimal systemic absorption when used as directed. Application should be limited to affected areas, avoiding prolonged use or occlusion to reduce the risk of adverse effects such as skin atrophy, telangiectasia, and hypothalamic-pituitary-adrenal axis suppression. Halotop Lotion is contraindicated in patients with hypersensitivity to halobetasol or any formulation components, as well as in viral, bacterial, or fungal skin infections. Caution is advised during use in pediatric populations and in areas of thin skin. Patients should adhere to prescribed duration and frequency to minimize potential side effects. Discontinuation should be gradual to prevent rebound dermatitis. Overall, Halotop Lotion offers an effective therapeutic option for managing severe inflammatory dermatoses under medical supervision.